Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study

James Lucocq; Jake Hawkyard; Beate Haugk; Omar Mownah; Krishna Menon; Takaki Furukawa; Yosuke Inoue; Yuki Hirose; Naoki Sasahira; Michael Feretis; Anita Balakrishnan; Carlo Ceresa; Brian Davidson; Rupaly Pande; Bobby Dasari; Lulu Tanno; Dimitrios Karavias; Jack Helliwell; Alistair Young; Quentin Nunes; Tomas Urbonas; Michael Silva; Alex Gordon-Weeks; Jenifer Barrie; Dhanny Gomez; Stijn Van Laarhoven; Francis Robertson; Hossain Nawara; Joseph Doyle; Ricky Bhogal; Ewen Harrison; Marcus Roalso; Debora Ciprani; Somaiah Aroori; Bathiya Ratnayake; Jonathan Koea; Gabriele Capurso; Ruben Bellotti; Stefan Stättner; Tareq Alsaoudi; Neil Bhardwaj; Srujan Rajesh; Fraser Jeffery; Saxon Connor; Andrew Cameron; Nigel Jamieson; Amy Sheen; Anubhav Mittal; Jas Samra; Anthony Gill; Keith Roberts; Kjetil Søreide; Sanjay Pandanaboyana

doi:10.1093/bjs/znae100

Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study

James Lucocq, Jake Hawkyard, Beate Haugk, Omar Mownah, Krishna Menon, Takaki Furukawa, Yosuke Inoue, Yuki Hirose, Naoki Sasahira, Michael Feretis, Anita Balakrishnan, Carlo Ceresa, Brian Davidson, Rupaly Pande, Bobby Dasari, Lulu Tanno, Dimitrios Karavias, Jack Helliwell, Alistair Young, Quentin NunesTomas Urbonas, Michael Silva, Alex Gordon-Weeks, Jenifer Barrie, Dhanny Gomez, Stijn Van Laarhoven, Francis Robertson, Hossain Nawara, Joseph Doyle, Ricky Bhogal, Ewen Harrison, Marcus Roalso, Debora Ciprani, Somaiah Aroori, Bathiya Ratnayake, Jonathan Koea, Gabriele Capurso, Ruben Bellotti, Stefan Stättner, Tareq Alsaoudi, Neil Bhardwaj, Srujan Rajesh, Fraser Jeffery, Saxon Connor, Andrew Cameron, Nigel Jamieson, Amy Sheen, Anubhav Mittal, Jas Samra, Anthony Gill, Keith Roberts, Kjetil Søreide, Sanjay Pandanaboyana

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: The clinical impact of adjuvant chemotherapy after resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia is unclear. The aim of this study was to identify factors related to receipt of adjuvant chemotherapy and its impact on recurrence and survival.

METHODS: This was a multicentre retrospective study of patients undergoing pancreatic resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia between January 2010 and December 2020 at 18 centres. Recurrence and survival outcomes for patients who did and did not receive adjuvant chemotherapy were compared using propensity score matching.

RESULTS: Of 459 patients who underwent pancreatic resection, 275 (59.9%) received adjuvant chemotherapy (gemcitabine 51.3%, gemcitabine-capecitabine 21.8%, FOLFIRINOX 8.0%, other 18.9%). Median follow-up was 78 months. The overall recurrence rate was 45.5% and the median time to recurrence was 33 months. In univariable analysis in the matched cohort, adjuvant chemotherapy was not associated with reduced overall (P = 0.713), locoregional (P = 0.283) or systemic (P = 0.592) recurrence, disease-free survival (P = 0.284) or overall survival (P = 0.455). Adjuvant chemotherapy was not associated with reduced site-specific recurrence. In multivariable analysis, there was no association between adjuvant chemotherapy and overall recurrence (HR 0.89, 95% c.i. 0.57 to 1.40), disease-free survival (HR 0.86, 0.59 to 1.30) or overall survival (HR 0.77, 0.50 to 1.20). Adjuvant chemotherapy was not associated with reduced recurrence in any high-risk subgroup (for example, lymph node-positive, higher AJCC stage, poor differentiation). No particular chemotherapy regimen resulted in superior outcomes.

CONCLUSION: Chemotherapy following resection of adenocarcinoma arising from intraductal papillary mucinous neoplasia does not appear to influence recurrence rates, recurrence patterns or survival.

Original language	English
Article number	znae100
Journal	The British journal of surgery
Volume	111
Issue number	4
DOIs	https://doi.org/10.1093/bjs/znae100
Publication status	Published - 3 Apr 2024

Keywords / Materials (for Non-textual outputs)

Aged
Female
Humans
Male
Middle Aged
Adenocarcinoma/pathology
Adenocarcinoma, Mucinous/pathology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Capecitabine/administration & dosage
Carcinoma, Pancreatic Ductal/pathology
Chemotherapy, Adjuvant
Gemcitabine
Neoplasm Recurrence, Local/epidemiology
Pancreatectomy
Pancreatic Intraductal Neoplasms/pathology
Pancreatic Neoplasms/pathology
Propensity Score
Retrospective Studies

Access to Document

10.1093/bjs/znae100Licence: Creative Commons: Attribution (CC-BY)

znae100Final published version, 421 KBLicence: Creative Commons: Attribution (CC-BY)

Cite this

Lucocq, J., Hawkyard, J., Haugk, B., Mownah, O., Menon, K., Furukawa, T., Inoue, Y., Hirose, Y., Sasahira, N., Feretis, M., Balakrishnan, A., Ceresa, C., Davidson, B., Pande, R., Dasari, B., Tanno, L., Karavias, D., Helliwell, J., Young, A., ... Pandanaboyana, S. (2024). Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study. The British journal of surgery, 111(4), Article znae100. https://doi.org/10.1093/bjs/znae100

@article{b867b609ca6248daa483d6051c1b242d,

title = "Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study",

abstract = "BACKGROUND: The clinical impact of adjuvant chemotherapy after resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia is unclear. The aim of this study was to identify factors related to receipt of adjuvant chemotherapy and its impact on recurrence and survival.METHODS: This was a multicentre retrospective study of patients undergoing pancreatic resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia between January 2010 and December 2020 at 18 centres. Recurrence and survival outcomes for patients who did and did not receive adjuvant chemotherapy were compared using propensity score matching.RESULTS: Of 459 patients who underwent pancreatic resection, 275 (59.9\%) received adjuvant chemotherapy (gemcitabine 51.3\%, gemcitabine-capecitabine 21.8\%, FOLFIRINOX 8.0\%, other 18.9\%). Median follow-up was 78 months. The overall recurrence rate was 45.5\% and the median time to recurrence was 33 months. In univariable analysis in the matched cohort, adjuvant chemotherapy was not associated with reduced overall (P = 0.713), locoregional (P = 0.283) or systemic (P = 0.592) recurrence, disease-free survival (P = 0.284) or overall survival (P = 0.455). Adjuvant chemotherapy was not associated with reduced site-specific recurrence. In multivariable analysis, there was no association between adjuvant chemotherapy and overall recurrence (HR 0.89, 95\% c.i. 0.57 to 1.40), disease-free survival (HR 0.86, 0.59 to 1.30) or overall survival (HR 0.77, 0.50 to 1.20). Adjuvant chemotherapy was not associated with reduced recurrence in any high-risk subgroup (for example, lymph node-positive, higher AJCC stage, poor differentiation). No particular chemotherapy regimen resulted in superior outcomes.CONCLUSION: Chemotherapy following resection of adenocarcinoma arising from intraductal papillary mucinous neoplasia does not appear to influence recurrence rates, recurrence patterns or survival.",

keywords = "Aged, Female, Humans, Male, Middle Aged, Adenocarcinoma/pathology, Adenocarcinoma, Mucinous/pathology, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Capecitabine/administration \& dosage, Carcinoma, Pancreatic Ductal/pathology, Chemotherapy, Adjuvant, Gemcitabine, Neoplasm Recurrence, Local/epidemiology, Pancreatectomy, Pancreatic Intraductal Neoplasms/pathology, Pancreatic Neoplasms/pathology, Propensity Score, Retrospective Studies",

author = "James Lucocq and Jake Hawkyard and Beate Haugk and Omar Mownah and Krishna Menon and Takaki Furukawa and Yosuke Inoue and Yuki Hirose and Naoki Sasahira and Michael Feretis and Anita Balakrishnan and Carlo Ceresa and Brian Davidson and Rupaly Pande and Bobby Dasari and Lulu Tanno and Dimitrios Karavias and Jack Helliwell and Alistair Young and Quentin Nunes and Tomas Urbonas and Michael Silva and Alex Gordon-Weeks and Jenifer Barrie and Dhanny Gomez and \{Van Laarhoven\}, Stijn and Francis Robertson and Hossain Nawara and Joseph Doyle and Ricky Bhogal and Ewen Harrison and Marcus Roalso and Debora Ciprani and Somaiah Aroori and Bathiya Ratnayake and Jonathan Koea and Gabriele Capurso and Ruben Bellotti and Stefan St{\"a}ttner and Tareq Alsaoudi and Neil Bhardwaj and Srujan Rajesh and Fraser Jeffery and Saxon Connor and Andrew Cameron and Nigel Jamieson and Amy Sheen and Anubhav Mittal and Jas Samra and Anthony Gill and Keith Roberts and Kjetil S{\o}reide and Sanjay Pandanaboyana",

note = "{\textcopyright} The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].",

year = "2024",

month = apr,

day = "3",

doi = "10.1093/bjs/znae100",

language = "English",

volume = "111",

journal = "The British journal of surgery",

issn = "0007-1323",

publisher = "Oxford University Press",

number = "4",

}

Lucocq, J, Hawkyard, J, Haugk, B, Mownah, O, Menon, K, Furukawa, T, Inoue, Y, Hirose, Y, Sasahira, N, Feretis, M, Balakrishnan, A, Ceresa, C, Davidson, B, Pande, R, Dasari, B, Tanno, L, Karavias, D, Helliwell, J, Young, A, Nunes, Q, Urbonas, T, Silva, M, Gordon-Weeks, A, Barrie, J, Gomez, D, Van Laarhoven, S, Robertson, F, Nawara, H, Doyle, J, Bhogal, R, Harrison, E, Roalso, M, Ciprani, D, Aroori, S, Ratnayake, B, Koea, J, Capurso, G, Bellotti, R, Stättner, S, Alsaoudi, T, Bhardwaj, N, Rajesh, S, Jeffery, F, Connor, S, Cameron, A, Jamieson, N, Sheen, A, Mittal, A, Samra, J, Gill, A, Roberts, K, Søreide, K & Pandanaboyana, S 2024, 'Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study', The British journal of surgery, vol. 111, no. 4, znae100. https://doi.org/10.1093/bjs/znae100

TY - JOUR

T1 - Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia

T2 - multicentre ADENO-IPMN study

AU - Lucocq, James

AU - Hawkyard, Jake

AU - Haugk, Beate

AU - Mownah, Omar

AU - Menon, Krishna

AU - Furukawa, Takaki

AU - Inoue, Yosuke

AU - Hirose, Yuki

AU - Sasahira, Naoki

AU - Feretis, Michael

AU - Balakrishnan, Anita

AU - Ceresa, Carlo

AU - Davidson, Brian

AU - Pande, Rupaly

AU - Dasari, Bobby

AU - Tanno, Lulu

AU - Karavias, Dimitrios

AU - Helliwell, Jack

AU - Young, Alistair

AU - Nunes, Quentin

AU - Urbonas, Tomas

AU - Silva, Michael

AU - Gordon-Weeks, Alex

AU - Barrie, Jenifer

AU - Gomez, Dhanny

AU - Van Laarhoven, Stijn

AU - Robertson, Francis

AU - Nawara, Hossain

AU - Doyle, Joseph

AU - Bhogal, Ricky

AU - Harrison, Ewen

AU - Roalso, Marcus

AU - Ciprani, Debora

AU - Aroori, Somaiah

AU - Ratnayake, Bathiya

AU - Koea, Jonathan

AU - Capurso, Gabriele

AU - Bellotti, Ruben

AU - Stättner, Stefan

AU - Alsaoudi, Tareq

AU - Bhardwaj, Neil

AU - Rajesh, Srujan

AU - Jeffery, Fraser

AU - Connor, Saxon

AU - Cameron, Andrew

AU - Jamieson, Nigel

AU - Sheen, Amy

AU - Mittal, Anubhav

AU - Samra, Jas

AU - Gill, Anthony

AU - Roberts, Keith

AU - Søreide, Kjetil

AU - Pandanaboyana, Sanjay

N1 - © The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].

PY - 2024/4/3

Y1 - 2024/4/3

N2 - BACKGROUND: The clinical impact of adjuvant chemotherapy after resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia is unclear. The aim of this study was to identify factors related to receipt of adjuvant chemotherapy and its impact on recurrence and survival.METHODS: This was a multicentre retrospective study of patients undergoing pancreatic resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia between January 2010 and December 2020 at 18 centres. Recurrence and survival outcomes for patients who did and did not receive adjuvant chemotherapy were compared using propensity score matching.RESULTS: Of 459 patients who underwent pancreatic resection, 275 (59.9%) received adjuvant chemotherapy (gemcitabine 51.3%, gemcitabine-capecitabine 21.8%, FOLFIRINOX 8.0%, other 18.9%). Median follow-up was 78 months. The overall recurrence rate was 45.5% and the median time to recurrence was 33 months. In univariable analysis in the matched cohort, adjuvant chemotherapy was not associated with reduced overall (P = 0.713), locoregional (P = 0.283) or systemic (P = 0.592) recurrence, disease-free survival (P = 0.284) or overall survival (P = 0.455). Adjuvant chemotherapy was not associated with reduced site-specific recurrence. In multivariable analysis, there was no association between adjuvant chemotherapy and overall recurrence (HR 0.89, 95% c.i. 0.57 to 1.40), disease-free survival (HR 0.86, 0.59 to 1.30) or overall survival (HR 0.77, 0.50 to 1.20). Adjuvant chemotherapy was not associated with reduced recurrence in any high-risk subgroup (for example, lymph node-positive, higher AJCC stage, poor differentiation). No particular chemotherapy regimen resulted in superior outcomes.CONCLUSION: Chemotherapy following resection of adenocarcinoma arising from intraductal papillary mucinous neoplasia does not appear to influence recurrence rates, recurrence patterns or survival.

AB - BACKGROUND: The clinical impact of adjuvant chemotherapy after resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia is unclear. The aim of this study was to identify factors related to receipt of adjuvant chemotherapy and its impact on recurrence and survival.METHODS: This was a multicentre retrospective study of patients undergoing pancreatic resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia between January 2010 and December 2020 at 18 centres. Recurrence and survival outcomes for patients who did and did not receive adjuvant chemotherapy were compared using propensity score matching.RESULTS: Of 459 patients who underwent pancreatic resection, 275 (59.9%) received adjuvant chemotherapy (gemcitabine 51.3%, gemcitabine-capecitabine 21.8%, FOLFIRINOX 8.0%, other 18.9%). Median follow-up was 78 months. The overall recurrence rate was 45.5% and the median time to recurrence was 33 months. In univariable analysis in the matched cohort, adjuvant chemotherapy was not associated with reduced overall (P = 0.713), locoregional (P = 0.283) or systemic (P = 0.592) recurrence, disease-free survival (P = 0.284) or overall survival (P = 0.455). Adjuvant chemotherapy was not associated with reduced site-specific recurrence. In multivariable analysis, there was no association between adjuvant chemotherapy and overall recurrence (HR 0.89, 95% c.i. 0.57 to 1.40), disease-free survival (HR 0.86, 0.59 to 1.30) or overall survival (HR 0.77, 0.50 to 1.20). Adjuvant chemotherapy was not associated with reduced recurrence in any high-risk subgroup (for example, lymph node-positive, higher AJCC stage, poor differentiation). No particular chemotherapy regimen resulted in superior outcomes.CONCLUSION: Chemotherapy following resection of adenocarcinoma arising from intraductal papillary mucinous neoplasia does not appear to influence recurrence rates, recurrence patterns or survival.

KW - Aged

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Adenocarcinoma/pathology

KW - Adenocarcinoma, Mucinous/pathology

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Capecitabine/administration & dosage

KW - Carcinoma, Pancreatic Ductal/pathology

KW - Chemotherapy, Adjuvant

KW - Gemcitabine

KW - Neoplasm Recurrence, Local/epidemiology

KW - Pancreatectomy

KW - Pancreatic Intraductal Neoplasms/pathology

KW - Pancreatic Neoplasms/pathology

KW - Propensity Score

KW - Retrospective Studies

U2 - 10.1093/bjs/znae100

DO - 10.1093/bjs/znae100

M3 - Article

C2 - 38659247

SN - 0007-1323

VL - 111

JO - The British journal of surgery

JF - The British journal of surgery

IS - 4

M1 - znae100

ER -

Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study

Abstract

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this